Platform·Healthcare/Life Sciences·August 3, 2026
CapVest-backed Curium to acquire Lantheus for up to $8 billion
The transaction would combine complementary radiopharmaceutical diagnostics and therapeutics businesses serving patients in more than 70 countries.
Takeaways
- Curium agreed to acquire Lantheus for up to approximately $8 billion.
- CapVest remains Curium's controlling shareholder.
- The companies expect the transaction to close in the first half of 2027.
BuyerCurium
TargetLantheus
SponsorCapVest
TypePlatform
GeographyBedford, Massachusetts
IndustryHealthcare
Sub-sectorLife Sciences
CapVest-backed Curium entered a definitive agreement to acquire Lantheus in a transaction valued at up to $8 billion.
Lantheus shareholders would receive $102.50.
The combination would join Curium's radiopharmaceutical manufacturing and therapeutics portfolio with Lantheus' U.S. radiodiagnostics business.
The companies expect the transaction to close in the first half of 2027, subject to shareholder and regulatory approvals.
Daily PE deal brief
Get tomorrow morning's tape in your inbox.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up before the workday starts.